皮肤鳞状细胞癌分期与监测影像共识指南
该研究通过德尔菲共识法,由45名多学科专家制定局部皮肤鳞状细胞癌(CSCC)分期与监测影像推荐。共识建议对转移风险≥15%的CSCC进行影像检查,CT为淋巴结分期和监测的首选模态,监测至少持续2年。
要点
- 对转移风险≥15%的CSCC建议分期和监测影像。
- 推荐影像的情形包括肿瘤转移担忧、骨侵犯、皮下脂肪外侵犯、大神经侵犯或直径≥4cm等。
- CT是淋巴结分期(84%共识)和监测(78%共识)的首选模态。
核心结论
- 该共识为局部CSCC的影像标准化提供专家框架,可望指导未来指南。
研究设计与样本
- 多学科专家小组德尔菲共识,3轮迭代调查(2025年1月至6月),45名专家完成全部轮次并纳入最终分析。
主要发现
- 专家组建议对转移风险至少15%的CSCC进行分期和监测。
- 对存在转移担忧、骨侵犯、皮下脂肪外侵犯、大神经侵犯或直径≥4cm的肿瘤达成共识或近共识推荐影像。
- 对低分化组织学合并直径≥2cm、淋巴血管侵犯合并皮下脂肪侵犯、或淋巴血管侵犯合并小神经周围侵犯的肿瘤也推荐影像。
- CT是淋巴结分期(38/45,84%)和监测(35/45,78%)的首选模态。
- 影像监测至少2年达成共识,至少3年达成近共识。
关键数值与推荐
- 共识定义为≥80%同意,近共识定义为70%–79%同意。
- 推荐分期和监测影像的转移风险阈值为至少15%。
临床怎么用
- 临床可依据共识推荐的情形(如转移风险≥15%、特定高危特征)对局部CSCC患者安排CT分期和监测影像。
- 监测影像至少持续2年,可考虑延长至3年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. OBJECTIVE: To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. EVIDENCE REVIEW: A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. FINDINGS: The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. CONCLUSIONS AND RELEVANCE: This study provides an expert consensus-based framework to standardize imaging in localized CSCC that may inform future guidelines.
引用
- Kassamali B, Schoenfeld JD, Sethi R, et al. Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2026. PMID: 42418212. doi:10.1001/jamadermatol.2026.2163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。